Income Statement (TTM)
Cinclus Pharma Holding AB (publ) Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|
| Revenue | 3 | 0 | 0 | 5 | 5 | 39 |
| Change (%) | -100.00 | NaN | ∞ | 0.00 | 744.43 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | ||
| Cost Of Sales | ||||||
| Change (%) | ||||||
| % of Revenue | ||||||
| Gross Operating Profit | 3 | 0 | 0 | 5 | 5 | 39 |
| Change (%) | -100.00 | NaN | ∞ | 0.00 | 744.43 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | ||
| SG&A | 33 | 37 | 36 | 37 | 39 | 50 |
| Change (%) | 13.16 | -3.26 | 2.97 | 6.04 | 26.91 | |
| % of Revenue | 1,107.52 | 804.67 | 853.25 | 128.24 | ||
| R&D | 158 | 139 | 117 | 137 | 145 | 178 |
| Change (%) | -11.73 | -16.17 | 17.25 | 5.81 | 22.77 | |
| % of Revenue | 5,335.54 | 2,983.78 | 3,157.01 | 459.00 | ||
| OpEx | 190 | 175 | 152 | 174 | 185 | 227 |
| Change (%) | -8.25 | -13.12 | 14.30 | 6.48 | 23.10 | |
| % of Revenue | 6,450.98 | 3,788.45 | 4,033.97 | 588.05 | ||
| Operating Income | -187 | -175 | -152 | -169 | -180 | -189 |
| Change (%) | -6.80 | -13.12 | 11.28 | 6.66 | 4.76 | |
| % of Revenue | -6,350.98 | -3,688.45 | -3,933.97 | -488.05 | ||
| Interest Expense | -7 | -1 | -9 | -8 | -6 | |
| Change (%) | -89.20 | -4.64 | -33.19 | |||
| % of Revenue | -245.90 | -190.52 | -181.68 | -14.37 | ||
| Net Income | -203 | -183 | -158 | -168 | -165 | -173 |
| Change (%) | -9.62 | -13.86 | 6.41 | -1.92 | 4.93 | |
| % of Revenue | -6,870.90 | -3,668.80 | -3,598.43 | -447.13 | ||
Source: Capital IQ
